People who feel so ill they needed treatment in intensive care can face a long recovery that may take months.
Category Archives: Body Optimization
Health24.com | Local company builds Covid-19 hospital tracking solution in 72 hours
On 7 May, there were more than 3.8 million confirmed Covid-19 cases and more than 267 000 deaths around the world, the Johns Hopkins Coronavirus Resource Centre indicates. In South Africa, we’ve been seeing a daily increase: the latest confirmed cases are 8 238, with 161 confirmed deaths.
With the Covid-19 pandemic placing unprecedented demands on hospitals around the world, health authorities worry about an insufficient supply of ventilators, beds and staff to help those infected.
Countries experiencing a shortage of these include South Sudan, Somalia and Venezuela. And to manage this crisis and establish hospital readiness in South Africa, Trixta, a collaborative low-code platform for business minds and software developers, have launched ReportCovidCase.com – a web app that was built in just 72 hours, and gives hospitals an indicator of how many cases they will have in the near future.
This initiative came after the company was approached by a private GP helping out at a well-known Cape Town hospital, expressing concerns about the lack of information about Covid-19 cases reaching hospitals. This prevents healthcare workers from knowing how many ventilators, beds and staff are required.
How the app works
The app enables local referring general practitioners (GPs) to log cases. This information then becomes available and accessible to hospitals in real-time, and helps them to plan their capacity and equipment needs. Best of all, it comes at no cost, and no training and set-up is required. Patient information can be anonymised, which means the process is rapid.
“A well-prepared hospital saves lives. Previously, GPs were relaying alerts to hospitals over WhatsApp and phone calls. However, with the anticipated upsurge that is likely to emerge particularly once the national lockdown is lifted, this will not be feasible,” said Trixta COO and Co-founder, Roger Norton, adding that if hospitals have the opportunity to start measuring what referring GPs are seeing, it will allow them to better prepare for the imminent rise in cases.
The platform is currently being trialled by 70 doctors in the greater Cape Town City Bowl area and one hospital, and has been built to allow multiple hospitals to sign up within one day. The intention is for it to be scaled further across South Africa and beyond, although funding is required to enable this.
“Up until now, this has been a completely pro bono project, but there is an increasingly urgent need to provide this kind of support to more hospitals throughout the country so that they can be properly prepared to face the impending spike in Covid-19 cases,” explained Norton.
Trixta will also be improving the platform over time to ensure that dashboards and reporting are improved, and it will also connect data from the web app to data from other sources, such as Pathcare and government databases, so as to track relationships between patients, and ultimately better monitor hotspot outbreaks.
READ | Why it’s even more important to distance while running – the danger is your ‘breath cloud’
READ | Blood pressure medications do not increase Covid-19 risk
READ | Covid-19: Interview with a Cape Town doctor on the frontlines
Image: Hush Naidoo/Unsplash
Health24.com | Coronavirus morning update: Latest on cigarettes, schools warned, and how travel bans saved lives
WHAT’S HAPPENING IN SA
Cases update:
The latest number of confirmed cases is 8 232.
The Western Cape has by far the most cases in the country, as it edges closer to 4 000 – with 3 994 total cases.
According to the latest update, 161 deaths have been recorded in the country.
So far, 292 153 tests have been conducted – more than 12 700 new tests.
READ MORE | All the confirmed cases of coronavirus in SA
Latest news:
Government has formally indicated that it will oppose a far-reaching court challenge to the lockdown cigarette sales ban – and has also made it clear that it will not hand over minutes of the National Coronavirus Command Council (NCCC) discussions regarding the ban because they are “classified”.
The Presidency has confirmed to News24 that cigarette companies are now allowed to manufacture and export tobacco products to other countries – but appear to be adamant that the ban on local sales must remain in place.
“Manufacture and export of cigarettes is already allowed in the regulations and not tailored for any company,” Presidency spokesperson Khusela Diko told News24.
“Government’s overriding objective is to save lives by enhancing adherence to the lockdown regulations. We are not making any morality judgements on cigarettes, hence manufacture and export is allowed as part of resumption of economic activity”.
READ MORE | Government refuses to show minutes of cigarette ban U-turn, says it’s ‘classified’
The Department of Basic Education has warned all schools against reopening prematurely.
The department said it was aware of some independent, private and public schools that were already preparing to reopen much earlier than required.
Spokesperson Elijah Mhlanga said some schools had even received pupils ahead of the schedule announced by Minister Angie Motshekga.
“In some schools, teachers have already been reporting for duty and parents’ meetings have been held where plans were announced to have learners back in school in May. The premature reopening of schools is not permitted, as the department is still finalising coronavirus school compliance protocols.
“The uniform standards will be applicable in schools as part of the measures put in place to protect pupils and teachers, reduce infection and save the academic year.
“Regulations were published on 29 April, in terms of the Disaster Management Act which listed education services under Level 4, as permitted on a date and schedule yet to be announced to direct when schools may reopen during Level 4,” said Mhlanga.
READ MORE | Opening of schools too soon is not permitted, warns education dept
As of Thursday night South Africans can move house again, as long as the country does not go back up to Alert Level 5.
Under regulations published by cooperative governance and traditional affairs (Cogta) minister Nkosazana Dlamini-Zuma, people and their household effects may move around South Africa on a once-off basis – even across provincial lines.
But there are terms and conditions – including that any move must happen by 7 June.
The rules are intended to allow people to move when they have entered a new lease agreement, either before or during lockdown, or where they have bought new homes and the transfer of the property has already gone through.
READ MORE | You can now move house under Level 4 – but only until 7 June
Uber Eats now delivers books from Exclusive Books. The food delivery service made the announcement on Thursday. The chain’s full range of books will be available, and delivery is free for the month of May.
“We’ve been working hard to expand our options on Uber Eats,” says the platform’s South African general manager, Ailyssa Pretorius.
“Great books are just as essential as great meals, something people will want at their fingertips in future.”
Apart from food deliveries during the lockdown, Uber Eats also delivers other essentials such as supplies from pharmacies, snack and nappies.
Book and stationery stores opened their doors on Friday, 1 May, as the country entered into Level 4 of the national lockdown.
READ MORE | You can now order from Exclusive Books on Uber Eats
In mid-March, Nelisa Jonas attended the funeral of a retired nurse in KwaDwesi township in Nelson Mandela Bay in the Eastern Cape. Soon after, a number of Covid-19 infections in Nelson Mandela Bay were traced back to this funeral. Since Jonas went to the funeral, she had to get tested.
Jonas told a local radio station that she lived in fear after her name was linked to the funeral on social media. She said on social media people were cautioned to stay away from her because she either tested positive or she was refusing to be tested.
Jonas said when she saw messages from the Department of Health encouraging those who had been at the funeral to get tested, she got tested at Motherwell Health Care Centre. Before she received her results, she says her name was already circulating on social media.
“The Department informed me that I tested negative and no one is taking responsibility on how my name landed up on social media. The community had not taken the news well and people are not comfortable with having me around because they believe I will pass on the virus to them,” Jonas said.
READ MORE | Covid-19: The battle against stigma in the Eastern Cape
On 31 March 2020 the Free State province reported its first Covid-19 death, and South Africa’s third.
The man who died was 85-year-old John Hlangeni. Whether he was the first or the third, to his family Hlangeni was more than just another Covid-19 statistic. When Spotlight recently spoke to his family members, their grief was still fresh. Hlangeni’s son, Gopolang Hlangeni, says his father was an avid reader who enjoyed telling stories. “He loved spending time with his great-grandchildren and watching wrestling with them on TV.
He was a soft man who enjoyed spending his time doing the Lord’s work. My father was a pastor at the Global Reconciliation Church and a respected man in his community. ”The family believes Hlangeni would still be alive if he had initially been tested for the virus and not just screened. Screening refers to checking for Covid-19 symptoms such as fever and dry cough, while testing refers to taking swabs from inside the mouth or nose and testing the samples in a laboratory.
Free State health authorities traced Hlangeni after he attended a church service that resulted in the province’s biggest cluster outbreak. The three-day church gathering was held from 9 to 11 March. A total of 895 people attended and over 70 Covid-19 cases were identified from the event.
READ MORE | Covid-19: How deaths are treated in the Free State
WHAT’S HAPPENING IN THE REST OF THE WORLD
Cases update:
For the latest global data, follow this interactive map from Johns Hopkins University & Medicine.
Late on Thursday night, positive cases worldwide were more than 3.81 million, while deaths were more than 267 000.
The United States had the most cases in the world – close to 1.25 million, as well as the most deaths – more than 75 000.
READ MORE | All the confirmed cases worldwide
Latest news:
The United Nations on Thursday issued a new appeal for $4.7 billion (R87 billion) in funding to “protect millions of lives and stem the spread of coronavirus in fragile countries.”
“I would like to see some of the wealthiest people in the world who are making money right now step up and be generous,” David Beasley, director of the UN’s World Food Programme, told a videoconference.
Beasley urged the world’s wealthiest people and companies to “step up in a major, major way,” saying that “if they do, we’ll all benefit – if they don’t, everyone has to pay a price.”
The money is on top of the $2 billion the UN already called for when it launched its global humanitarian response plan on 25 March. It has received about half of that money so far.
“The most devastating and destabilising effects” of the novel coronavirus pandemic “will be felt in the world’s poorest countries,” the UN under-secretary general for humanitarian affairs, Mark Lowcock, said in a statement.
“Unless we take action now, we should be prepared for a significant rise in conflict, hunger and poverty. The specter of multiple famines looms,” he warned.
READ MORE | UN asks super-wealthy to ‘step up’ and donate for coronavirus relief
President Donald Trump is worried wearing a face mask in public could ruin his chances of being reelected, according to a new report from the Associated Press (AP).
The president has never been seen wearing a mask in public, and drew criticism on Tuesday for failing to wear a face mask during a tour of a Honeywell plant in Arizona – going against both CDC guidance and a rule requiring workers at the factory to wear them.
Trump reportedly believes that wearing a face mask would “send the wrong message” that he is more focused on the current health threat than reopening the economy, one administration source and two campaign officials told the AP.
Aides believe that getting the US economy up and running again is key to winning in November.
One of the officials added that Trump is afraid he might look ridiculous wearing a face mask, and that the image could be used against him in attack ads.
This isn’t the first time that Trump has publicly gone against coronavirus safety guidelines.
READ MORE | Donald Trump won’t wear a mask in public because he’s afraid he might look ridiculous
LATEST RESEARCH
While we know that Covid-19 can cause severe respiratory symptoms and patients can die because of acute respiratory distress syndrome (ARDS), scientists are investigating what else can cause a fatal outcome in Covid-19 patients.
There have been reports on immune systems that go into overdrive, causing serious complications. Now, however, it appears that blood clots in the lungs can also cause serious outcomes.
A study, led by clinician-scientists at RCSI University of Health Scientists, found that Irish Covid 19 patients experienced more severe complications and even death, because of blood clotting in the lungs.
This study was published in the British Journal of Haematology and was covered in a press release.
READ MORE | How blood clots can cause severe Covid-19 complications
Many people with high blood pressure, medically known as hypertension, have been wondering whether their blood pressure medications could increase their risk of developing Covid-19, the disease caused by the new coronavirus. However, a new study, led by researchers from NYU Grossman School of Medicine, found that common high blood pressure drugs did not increase the risk of contracting Covid-19, or of developing severe disease.
This came after the American Heart Association, the American College of Cardiology and the Heart Failure Society of America issued a joint statement on 17 March, wherein they called for urgent research into whether high blood pressure medications worsen Covid-19 patient outcomes, a news release by EurekAlert reports.
The study was recently published in the New England Journal of Medicine.
The topic became popular recently when some experts questioned the relationship between common blood pressure medications and their ability to increase the risk of Covid-19. Among them was a letter published in the Lancet. The author recommended stopping ACE Inhibitors and ARBs – which relaxes the veins and arteries to lower blood pressure – in Covid-19 patients, based on seemingly legitimate theoretical concerns. For people with hypertension, this led to a wave of panic, causing them to stop taking their medication.
READ MORE | Blood pressure medications do not increase Covid-19 risk
Many countries have implemented lockdown in an effort to contain the Covid-19 pandemic. Part of this strategy has been travel restrictions and bans, and, according to a new study by computer modelling experts at Stanford University, millions more people across the European Union could have contracted the disease had these international travel bans not been enforced.
The report, published in Computer Methods in Biomechanics and Biomedical Engineering, utilised a newly developed mathematical epidemiology simulation which calculated the consequences of limiting air travel across the 27 EU states on the spread of Covid-19.
The simulation was able to estimate figures for the spread of Covid-19 for each country, if travel bans were removed.
Since the team involved in the study can virtually lift travel restrictions between individual communities, states, or countries, and therefore analyse the potential gradual changes in spreading patterns and outbreak dynamics, their new model could play a significant role in political decision-making, one of the researchers said.
“Our results demonstrate that mathematical modelling can provide guidelines for political decision making with the ultimate goal to gradually return to normal while keeping the rate of new Covid-19 infections steady and manageable.”
Studies are beginning to show that, in rare cases, people with severe Covid-19 may develop the serious nervous system disorder known as Guillain-Barre syndrome.
“Guillain-Barre syndrome is a well-known condition in which one’s immune system targets peripheral nerves as foreign and attacks them, resulting in the cardinal features of the disease,” explained Dr Anthony Geraci, who directs neuromuscular medicine at Northwell Health in Great Neck, New York.
The symptoms of the disorder “include weakness, areflexia [absence of reflexes], paraesthesia [tingling], and in some cases facial weakness and ataxia [poor balance],” Geraci said.
It’s not uncommon for severe cases of infectious disease to trigger Guillain-Barre, experts noted. According to the Italian authors of a new study, the syndrome has also been seen in patients battling Epstein-Barr virus, cytomegalovirus and, most notably, infection with mosquito-borne Zika.
READ MORE | Some Covid-19 patients stricken by Guillain-Barre syndrome
HEALTH TIPS (as recommended by the NICD and WHO)
• Maintain physical distancing – stay at least one metre away from somebody who is coughing or sneezing
• Practise frequent hand-washing, especially after direct contact with ill people or their environment
• Avoid touching your eyes, nose and mouth, as your hands touch many surfaces and could potentially transfer the virus
• Practise respiratory hygiene – cover your mouth with your bent elbow or tissue when you cough or sneeze. Remember to dispose the tissue immediately after use.
READ MORE: Coronavirus 101
Image credit: Getty Images
More, Better, Different, Purpose

In his book Road to Purpose, Kenneth Behring shared how his life went through four phases.
The first phase was more – more money, more success, more friends, etc.
The second phase was better – a better home, better possessions, better vacations, etc.
The third phase was different – new experiences, new possessions, etc.
And the final phase was purpose – meaning, fulfillment, contribution, and making a difference in other people’s lives.
Behring claimed to have moved through these phases in linear order, but you have more flexible options here. You can shift among these four different types of growth throughout your life. You could be living a very purposeful life and still want to explore more, better, and different, for instance.
If you think about which type of growth most appeals to you now, which of these four would you pick? What feels most important to you? Where do you sense the greatest need or desire?
For me it would depend on when you ask me. This year I’m mainly focused on better. Lately I’ve been investing in creating better habits, developing better systems, and especially making Conscious Growth Club even better. My wife Rachelle has a similar focus. Afterwards we both agree that it would be nice to explore some different, especially when traveling becomes viable again.
When you have a primary desire or focus, do your best to avoid opportunity blindness to the other three modes of growth. Realize that different could lead to better. Purpose could lead to more. And so on.
If you get stuck trying to make progress with your preferred mode of self-development, try broadening your perspective, and consider the other three modes. One of them may hold the key to releasing that stuckness.
Health24.com | How a llama named Winter could help fight Covid-19
We can’t help liking llamas with their fluffy faces and spindly legs.
But it seems that the llama has now become significant for a particular reason – its blood contains an antibody that could potentially neutralise SARS-CoV-2.
A new study published in the journal Cell on Tuesday 5 May 2020 stated that these antibodies can help neutralise the novel coronavirus, known for causing Covid-19. This comes from research of four years ago. The international research team found that the antibodies from a then nine-month-old llama named Winter could neutralise both SARS-CoV-1 and Mers-Cov over a period of six weeks.
Both these coronaviruses were known for causing outbreaks in 2003 and 2012. Now, SARS-CoV-2 is sweeping across the globe with dire consequences.
On track to a solution?
In the new research, Winter’s (now four years old) antibodies also had the same neutralising effect on SARS-CoV-2.
But why a llama? According to the experts, the small size of their antibodies makes them more likely to connect successfully to different parts of the virus.
“The binding of this antibody to spike is able to prevent attachment and entry, which effectively neutralises the virus,” Daniel Wrapp, Dartmouth PhD candidate and co-author, explained in a report.
Scientists hope that a treatment plan could emerge from this new research.
“Vaccines have to be given a month or two before infection to provide protection,” McLellan said in the statement. “With antibody therapies, you’re directly giving somebody the protective antibodies and so, immediately after treatment, they should be protected.”
Antibody therapy can also be administered to those who are already infected with Covid-19, as it might lessen the symptoms.
Is this the first time that the llama is considered for antibodies?
According to an article in the New York Times, llama antibodies were also used in HIV and influenza research. Research published in PLOS Pathogens in 2014 stated that a combination of llama antibodies can help destroy a large selection of HIV viruses. These antibodies were described as “broadly neutralising” antibodies, very similar to human antibodies.
How long before we see a treatment?
As with any medical development, more research and tests would be needed before we see this as a treatment used in a clinical setting.
“There is still a lot of work to do to try to bring this into the clinic,” Xavier Saelens, a molecular virologist at Ghent University in Belgium and co-author said in a report. “If it works, llama Winter deserves a statue.”
Image credit:
Coronavirus: Does obesity increase the risk?
Could the amount of fat in our body increase complications with Covid-19?
Blood thinners may improve survival among hospitalized COVID-19 patients
Treating hospitalized COVID-19 patients with anticoagulants — blood thinners that slow down clotting — may improve their chances of survival, researchers from the Mount Sinai COVID Informatics Center report. The study, published in the May 6 issue of the Journal of the American College of Cardiology, could provide new insight on how to treat and manage coronavirus patients once they are admitted to the hospital.
The study found that hospitalized COVID-19 patients treated with anticoagulants had improved outcomes both in and out of the intensive care unit setting. The research also showed that the difference in bleeding events among patients treated with and without anticoagulants was not significant. The Mount Sinai researchers say their work outlines an important therapeutic pathway for COVID-19 patients.
“This research demonstrates anticoagulants taken orally, subcutaneously, or intravenously may play a major role in caring for COVID-19 patients, and these may prevent possible deadly events associated with coronavirus, including heart attack, stroke, and pulmonary embolism,” says senior corresponding author Valentin Fuster, MD, PhD, Director of Mount Sinai Heart (the nation’s number six ranked hospital in Cardiology/Heart Surgery) and Physician-in-Chief of The Mount Sinai Hospital. “Using anticoagulants should be considered when patients get admitted to the ER and have tested positive for COVID-19 to possibly improve outcomes. However, each case should be evaluated an individualized basis to account for potential bleeding risk.”
The publication of this study follows recent research out of the Icahn School of Medicine at Mount Sinai that shows a large number of patients hospitalized with COVID-19 have developed high levels of life-threatening blood clots, leading to potentially deadly thromboembolic events.
A team of investigators evaluated records of 2,773 confirmed COVID-19-positive patients admitted to five hospitals in the Mount Sinai Health System in New York City (The Mount Sinai Hospital, Mount Sinai West, Mount Sinai Morningside, Mount Sinai Queens, and Mount Sinai Brooklyn) between March 14 and April 11, 2020. They specifically looked at survival rates for patients placed on blood thinners versus those not placed on blood thinners. The researchers took certain risk factors into account before evaluating the effectiveness of anticoagulation, including age, ethnicity, pre-existing conditions, and those already on blood thinners.
Of the COVID-19 patients analyzed, 786 (28 percent) received a full-treatment dose of anticoagulants — a higher dose than what is typically given for blood clot prevention, and one that is usually given to those who already have clots or are suspected to have clots. Treatment with anticoagulants was associated with improved hospital survival among COVID-19 patients both in and out of the intensive care unit setting. Of the patients who did not survive, those on anticoagulants died after spending an average of 21 days in the hospital, compared to the non- anticoagulant patients who died after an average of 14 days in the hospital. The effect of anticoagulation had a more pronounced effect on ventilated patients — 62.7 percent of intubated patients who were not treated with anticoagulants died, compared to 29.1 percent for intubated patients treated with anticoagulants. Of the intubated patients who did not survive, those with no anticoagulants died after 9 days, while those on anticoagulants died after 21 days.
All patients in the study had blood work done when they arrived at the hospital, which included measuring various inflammatory markers. The analysis of their records showed patients who received anticoagulants had higher inflammatory markers compared to patients not treated with anticoagulants. This may suggest patients with more severe illness may benefit from anticoagulants early on.
The observational study also explored the association of systemic anticoagulant treatment with bleeding events. Major bleeding was defined as 1) hemoglobin <7 g/dL and any red blood cell transfusion; 2) at least 2 units of red blood cell transfusion within 48 hours; or 3) a diagnosis code for major bleeding including intracranial hemorrhage; hematemesis; melena; peptic ulcer with hemorrhage; colon, rectal, or anal hemorrhage; hematuria; ocular hemorrhage; and acute hemorrhagic gastritis. Among those who did not receive anticoagulants, 38 (1.9 percent) patients had bleeding events, compared to 24 (3 percent) among those who received anticoagulants, p=0.2).
“We are hopeful that this report of the association of anticoagulation therapy with improved survival will be confirmed in future investigations. The astute scientists at Mount Sinai continue to analyze our data on COVID-19 patients in order to contribute to worldwide efforts to find effective treatments,” says David Reich, MD, President and Chief Operating Officer of The Mount Sinai Hospital.
“As a cardiologist who has been on service caring for COVID-19 patients for the last three weeks, I have observed an increased amount of blood clot cases among hospitalized patients, so it is critical to look at whether anticoagulants provide benefits for them,” says co-researcher Anu Lala, MD, Assistant Professor of Medicine (Cardiology) at the Icahn School of Medicine at Mount Sinai. “It’s important to note that further analysis and prospective studies are required to determine the effectiveness for widespread use of anticoagulants in hospitalized COVID-19 patients.”
“This study is opening the door for a more extensive study that will be carried out with 5,000 COVID-19-positive patients, where we will evaluate the effectiveness of three types of antithrombotic therapy — oral antithrombotic, subcutaneous heparin, and intravenous heparin — and then perhaps engage our data for prospective clinical trials,” says senior author Girish Nadkarni, MD, Co-Director of the Mount Sinai COVID Informatics Center. “We are excited about these preliminary results that may have a positive impact on COVID-19 patients and potentially give them a greater chance of survival, although more studies are needed.”
Prediction tool shows how forest thinning may increase Sierra Nevada snowpack
The forest of the Sierra Nevada mountains is an important resource for the surrounding communities in Nevada and California. Thinning the forest by removing trees by hand or using heavy machinery is one of the few tools available to manage forests. However, finding the best way to thin forests by removing select trees to maximize the forest’s benefits for water quantity, water quality, wildfire risk and wildlife habitat remains a challenge for resource managers. The U.S. Forest Service is leading an effort to balance all these challenges in landscape-scale forest restoration planning as part of the Lake Tahoe West Restoration Partnership.
As part of this effort, University of Nevada, Reno’s Adrian Harpold recently led a team in developing a modeling tool to focus on the issue of water quantity. The tool predicts how different approaches to thinning the forest impact snowpack accumulation in Lake Tahoe, which controls how much water is available for downstream communities such as Reno.
“The snowpack we’ve relied upon is under pressure from years of fire suppression that increased tree density, combined with the effects of climate change and warming temperatures,” Harpold, natural resources & environmental science assistant professor with the College of Agriculture, Biotechnology & Natural Resources, said.
He explained that too many trees means less snow reaches the ground. In addition, when many trees are clumped together, they warm up and release heat, which can melt the snow on the ground. However, too few trees means the snowpack is less protected from the sun and wind, which also melt snow.
The tool, developed with funding from the College’s Experiment Station and the U.S. Forest Service, was built to specifically model the west shore of Lake Tahoe, which the team felt was a good sample of the Sierra Nevada forest. The team initially created a small-scale high-resolution model using data collected with 3D laser scanners, called “LiDAR.”
“The LiDAR data lets us see individual trees, which we use to ‘virtually thin’ the forest by taking trees out of the model,” he said. “As such, it lets us create a thinning experiment that’s realistic. We can then represent different management actions, such as removing trees below certain heights.”
His team, including the post-doctoral scholar Sebastian Krogh, graduate student Devon Eckberg, undergraduate students Makenzie Kohler and Gary Sterle, the College’s Associate Professor of Remote Sensing Jonathan Greenberg and University of Arizona’s Patrick Broxton, tested the model’s accuracy by conducting thinning experiments and comparing the predictions to measurements in the real forest. Results were discussed in a recently published article on the proof-of-concept for using high-resolution modeling to predict the effect of forest thinning for snow, for which Harpold was the lead author.
Once the team determined the model was working correctly, they increased the model size to represent Lake Tahoe’s western shore. Results are discussed in another recently published article on using the model to predict the effects of forest thinning on the northern Sierra Nevada snowpack, led by Krogh with Harpold, Broxton and the Forest Service’s Patricia Manley as co-authors. Their experiments showed that overall, more trees removed means more snow maintained. However, there are beneficial ways and detrimental ways to remove trees. The method that appeared to be most effective was removing dense trees that had many leaves and branches and were shorter than about 50 feet, leaving behind taller trees. There were also differences in effectiveness depending on the elevation, the slope and the direction the slope was facing.
Harpold plans to continue expanding the model, testing to see if it will work for Lake Tahoe’s eastern shore and in the American River Basin, with the ultimate goal of providing a tool for Forest Service decision-makers and others to inform their forest-thinning plans.
The water-quantity tool is one of many different modeling tools being developed with funding from the Forest Service as part of the Tahoe-Central Sierra Initiative, which aims to quickly restore the forest to improve the health and resilience of Sierra Nevada mountains and maximize the benefits that the forest provides.
“My decision-support tool for water quantity would be a smaller piece in a larger toolkit to help determine how and where to thin the forests,” Harpold said.
Other tools being designed to predict forest-thinning impacts include a tool to predict impact on wildfire spread, a tool to predict impact on smoke, a tool to predict impact on endangered and threatened species, a tool to predict sediment flow into Lake Tahoe and a tool to predict economic impact.
Olanzapine may help control nausea, vomiting in patients with advanced cancer
Olanzapine, a generic drug used to treat nervous, emotional and mental conditions, also may help patients with advanced cancer successfully manage nausea and vomiting unrelated to chemotherapy. These are the findings of a study published Thursday, May 7 in JAMA Oncology.
Charles Loprinzi, M.D., a Mayo Clinic medical oncologist, played a leadership role in this work in conjunction with Rudolph Navari, M.D., of The University of Alabama at Birmingham.
“It’s well-appreciated by most people that patients receiving cancer chemotherapy suffer from nausea and vomiting,” explains Dr. Loprinzi. “However, it’s less well-appreciated that patients with advanced cancer also have significant problems with nausea and vomiting that are unrelated to chemotherapy.”
Drs. Loprinzi and Navari found limited research regarding nausea and vomiting in patients with advanced cancer unrelated to chemotherapy, so they decided to conduct a clinical trial.
The colleagues, along with other collaborators, conducted a randomized, placebo-controlled trial in 30 patients with advanced cancer who had not recently received chemotherapy or radiation therapy but did have substantial trouble with nausea and vomiting. Researchers randomly assigned patients to receive a low-dose of olanzapine or a placebo daily. Neither the trial participants nor their clinicians knew whether participants were receiving olanzapine or a placebo.
Prior to starting their medications on the first day of the study, participants rated their nausea over the previous 24 hours on a scale of 0-10, with 0 being none and 10 being as bad as it could be. Participants continued to rate their nausea every day at about the same time of day for the duration of the study.
When the study was unblinded, the research team learned that all 30 participants recorded nausea scores of 8-10 on the first day of the study. After one day and one week, nausea scores in the 15 patients who received a placebo were all still 8-10 out of 10. In contrast, the 15 patients who received olanzapine had scores of 2-3 out of 10 after one day and 0-3 out of 10 after one week. Correspondingly, these patients reported less vomiting, better appetite and better well-being. No patient-reported adverse events were observed among trial participants receiving olanzapine.
“Olanzapine given at 5 milligrams per day for seven days markedly improved patient quality of life with no side effects,” says Dr. Navari. “And as a generic drug, it’s also relatively affordable, with a one-month supply often costing anywhere from $10 to $15.”
“Current guidelines for the management of nausea and vomiting in patients with advanced cancer have not specifically indicated that one drug looks substantially better than a variety of other drugs,” says Dr. Loprinzi. “However, we believe the present results may be viewed as a best practice for treating nausea and vomiting in patients with advanced cancer-associated nausea and vomiting.”
Story Source:
Materials provided by Mayo Clinic. Original written by Kevin Punsky. Note: Content may be edited for style and length.
Coronavirus: Black Britons face ‘twice the risk’ of death, says ONS
Location and wealth do not fully explain the risk compared with white people, new analysis suggests.




